Verkazia: Ciclosporin/Cyclosporine A 0.1% Cationic Emulsion (CsA CE)
- Lack of availability of a commercial preparation of topical CsA, technical difficulties in dispensing eye drops, and legal restrictions on its topical use in many countries have precluded widespread use in VKC1
Santen developed CsA CE 0.1% in order to increase the bioavailability of ciclosporin A at the
- Verkazia® is approved in the EU and Canada for the treatment of severe VKC in children from 4 years of age through adolescence2,3
- This product is not approved for use in the US
1. Leonardi A et al. Ophthalmol Ther. 2013;2:73-88; 2. Verkazia (cyclosporine 0.1%). Product Monograph. Santen Incorporated; Emeryville, California. December 21, 2018; 3. Verkazia (ciclosporin 1 mg/mL). Summary of Product Characteristics. Santen Oy; Tampere, Finland. March 2, 2017.